Language:

Treatment of diffuse diabetic maculopathy with intravitreal triamcinolone and laser photocoagulation: randomized clinical trial with morphological and functional evaluation

Arquivos brasileiros de oftalmologia, 2011-09, Vol.74 (5), p.343-347 [Peer Reviewed Journal]

This work is licensed under a Creative Commons Attribution 4.0 International License. ;ISSN: 0004-2749 ;ISSN: 1678-2925 ;EISSN: 1678-2925 ;DOI: 10.1590/S0004-27492011000500007 ;PMID: 22183994

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Treatment of diffuse diabetic maculopathy with intravitreal triamcinolone and laser photocoagulation: randomized clinical trial with morphological and functional evaluation
Author: Gil, Alberto Luiz ; Azevedo, Mirela Jobim de ; Tomasetto, Giovani Generali ; Muniz, Carlos Henrique Gervini ; Lavinsky, Jacó
Subjects: Aged ; Combined Modality Therapy - methods ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - therapy ; Double-Blind Method ; Female ; Glucocorticoids - administration & dosage ; Humans ; Intravitreal Injections ; Laser Coagulation ; Macular Edema - etiology ; Macular Edema - pathology ; Macular Edema - physiopathology ; Macular Edema - therapy ; Male ; Middle Aged ; OPHTHALMOLOGY ; Tomography, Optical Coherence ; Treatment Outcome ; Triamcinolone Acetonide - administration & dosage ; Visual Acuity
Is Part Of: Arquivos brasileiros de oftalmologia, 2011-09, Vol.74 (5), p.343-347
Description: Treatment of diffuse macular edema in diabetes mellitus is currently unsatisfactory. The purpose of this double blind randomized clinical trial was to compare the treatment of diffuse diabetic macular edema with intravitreal triamcinolone or laser in type 2 diabetes mellitus patients using a morphofunctional assessment. Fourteen patients (21 eyes) with clinically significant diffuse macular-edema, previously untreated and with a macular thickness >250 µm at optical coherence tomography were randomized for treatment with laser or intravitreal injection of triamcinolone acetate. Optical coherence tomography, biomicroscopy, fundoscopy, fluorescein angiography, tonometry, scotometry, visual and contrast acuities were performed at 0, 1, 3 and 6 months. At pre-treatment stage, Laser (n=9) and Triamcinolone (n=12) groups did not differ regarding retinal thickness, visual and contrast acuities. In Triamcinolone group macular thickness decreased after 1 month (424.1 ± 19.9 µm to 358.4 ± 18.2 µm; p=0.04) and started to return to the initial values in the 3(rd) month (p=0.02). No changes occurred in macular scotometry and visual and contrast acuities. No side effects were observed with both treatments. During the study macular thickness diminished in the triamcinolone group, especially in the first month of treatment. At 3 and 6 months there was no difference. Macular thickness did not change during the study in the laser group. In the study sample it was not possible to demonstrate differences relates to visual acuity and scotometry between the two groups. CLINICALTRIALS.GOV IDENTIFIER: NCT00668239.
Publisher: Brazil: Conselho Brasileiro de Oftalmologia
Language: English;Portuguese
Identifier: ISSN: 0004-2749
ISSN: 1678-2925
EISSN: 1678-2925
DOI: 10.1590/S0004-27492011000500007
PMID: 22183994
Source: IngentaConnect Free/Open Access Journals
SciELO
GFMER Free Medical Journals
MEDLINE

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Treatment of diffuse diabetic maculopathy with intravitreal triamcinolone and laser photocoagulation: randomized clinical trial with morphological and functional evaluation

This work is licensed under a Creative Commons Attribution 4.0 International License. ;ISSN: 0004-2749 ;ISSN: 1678-2925 ;EISSN: 1678-2925 ;DOI: 10.1590/S0004-27492011000500007 ;PMID: 22183994

Searching Remote Databases, Please Wait